Taiho Pharmaceutical

Araris Biotech AG Announces Research Collaboration with Taiho Pharmaceutical to Develop Next-Generation ADCs Using Araris’ Proprietary Linker-Conjugation Technology

Retrieved on: 
Wednesday, November 8, 2023
Taiho Pharmaceutical, Spacecraft, Fine chemical, Pharmaceutical industry, Taiho

AU ZH, Switzerland, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris”), a Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs), today announced they have entered a collaboration agreement under which Araris will use its proprietary linker-conjugation platform to generate novel ADCs against undisclosed targets provided by Taiho Pharmaceutical Co., Ltd., a Japanese R&D-driven specialty pharma company with a focus on oncology.

Key Points: 
  • AU ZH, Switzerland, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris”), a Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs), today announced they have entered a collaboration agreement under which Araris will use its proprietary linker-conjugation platform to generate novel ADCs against undisclosed targets provided by Taiho Pharmaceutical Co., Ltd., a Japanese R&D-driven specialty pharma company with a focus on oncology.
  • ADCs delivered by Araris will be further tested and evaluated by Taiho.
  • The financial terms of the collaboration agreement were not disclosed.
  • “We are proud to enter a collaboration with Taiho Pharmaceutical and look forward to working with the Taiho team to develop next-generation ADCs with improved efficacy and tolerability,” said Dragan Grabulovski, Ph.D., acting chief executive officer of Araris.

Acutis Biosciences' CSO Dr. Abdel Halim Co-Authors a Precision Medicine Study in NEJM

Retrieved on: 
Thursday, September 7, 2023
Tissue, DNA, The New England Journal of Medicine, LDT, Qualitative research, Circulating tumor DNA, Therapy, NGS, 2005 in television, Liquid biopsy, CTA, Toxicology, Taiho Pharmaceutical, Biomarker, IHC, NEJM, CLIA, Patient, Medicine, Neoplasm, CDX, FDA, FGFR2, PCR, Cholangiocarcinoma, Medical imaging, Pharmaceutical industry, Medical device, Molecular diagnostics

Study demonstrates the clinical value of circulating tumor DNA (ctDNA) in molecular profiling.

Key Points: 
  • Study demonstrates the clinical value of circulating tumor DNA (ctDNA) in molecular profiling.
  • The study demonstrated the clinical value of circulating tumor DNA (ctDNA) in molecular profiling to assess patient's eligibility for targeted therapeutics.
  • With ctDNA blood samples you are guaranteed as low as 1% failure rate compared to tumor tissues" said Dr. Halim.
  • Acutis CEO Jibreel Sarij added, "Dr. Halim and his team are making significant impact to bring forward clinical research testing and genomic profiling to enable biopharma with deeper insights and transform precision medicine".

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline Update

Retrieved on: 
Tuesday, February 28, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Death, CD73, Safety, KIT, Cancer, TIGIT, PD-1, NYSE, Research, Lung cancer, Risk, G&A, Interim, Phase II, Standard of care, Patient, R, OS, Progression-free survival, Inflammation, Research and development, ORR, Docetaxel, NSCLC, GI, Partnership, PFS, CRPC, Administration, Taiho Pharmaceutical, Lung, Pharmaceutical industry, Mineral wool, Cryptocurrency, Taiho

“During 2022, Arcus established itself as a late-stage company and made tremendous progress in the advancement of its pipeline.

Key Points: 
  • “During 2022, Arcus established itself as a late-stage company and made tremendous progress in the advancement of its pipeline.
  • There are also four ongoing Phase 2 studies to evaluate domvanalimab-based combinations: three in NSCLC and one in upper GI cancer.
  • In the fourth-quarter 2022, Arcus recognized $26 million in license and development service revenues for programs optioned by Gilead.
  • G&A expenses were $104 million for the full-year 2022, compared to $72 million for the same period in 2021.

Rheumatoid Arthritis Market is Expected to Showcase Significant Growth in the 7MM at a Minimal CAGR of 1.9% During the Study Period (2019-2032), Predicts DelveInsight

Retrieved on: 
Monday, January 9, 2023
Taisho Pharmaceutical, Eli Lilly and Company, GlaxoSmithKline, Disease-modifying antirheumatic drug, Horizon Therapeutics, Autoimmune disease, Joint, EU4, Rheumatoid arthritis, Society, Inflammation, LAS, Gilead Sciences, R, Research, Tissue, JTE, Taiho Pharmaceutical, Patient, Olokizumab, Bristol Myers Squibb, Abivax, FDA, Immune system, United Kingdom, Diagnosis, US, Pharmaceutical industry, Frankincense, Copper, Ozoralizumab, Pfizer, Phase

LAS VEGAS, Jan. 9, 2023 /PRNewswire/ -- DelveInsight's Rheumatoid Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, rheumatoid arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the 7MM [the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the rheumatoid arthritis market size in the 7MM was approximately USD 27 billion in 2021.
  • According to the assessment done by DelveInsight, the estimated total rheumatoid arthritis prevalent population in the 7MM was approximately 4.7 million in 2021.
  • However, clinical trials of rheumatoid arthritis show that remission of symptoms is more common when rheumatoid arthritis treatment with disease-modifying antirheumatic medicines begins early (DMARDs).
  • DelveInsight estimates that there were approximately 4.7 million prevalent cases of rheumatoid arthritis in the 7MM in 2021.

Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer

Retrieved on: 
Monday, September 12, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Neuroscience, Lists of diseases, Safety, Awareness, Cell proliferation, CRC, Social media, Patient, Oncology, Cardiology, Foundation, Human, Taiho Pharmaceutical, Urology, Quality of life, Disease, Organic, Oxaliplatin, Allergy, Teaching hospital, International Agency for Research on Cancer, Growth, Metabolism, Thymidine phosphorylase, Colorectal cancer, International development, DCR, TP, DNA, Trifluridine/tipiracil, Trifluridine, Partnership, Irinotecan, Progression-free survival, Research and development, Group, Health, Incidence, Twitter, World Health Organization, LinkedIn, Survival, ORR, Caregiver, Death, Heart, Multimedia, PFS, Pharmaceutical industry, Medical imaging, Birth control, OS, Research, Bevacizumab, Laboratoires Servier, Facebook, Cancer

Combining trifluridine/tipiracil with bevacizumab demonstrated the potential to extend survival in these patients who have limited therapeutic options.

Key Points: 
  • Combining trifluridine/tipiracil with bevacizumab demonstrated the potential to extend survival in these patients who have limited therapeutic options.
  • New treatment options are urgently needed as we seek to reduce the growing global burden of colorectal cancer.
  • SUNLIGHT is a multinational, open-label, active-controlled, two-arm Phase III trial to investigate the efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil alone, in patients with refractory mCRC following two chemotherapy regimens.
  • The primary objective was to demonstrate the superiority of trifluridine/tipiracil plus bevacizumab over trifluridine/tipiracil alone, in terms of OS (primary endpoint).

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Wednesday, August 10, 2022
MDS, U.S. Securities and Exchange Commission, CD19, Survival, ASCO, Exercise, Risk, BID, Private Securities Litigation Reform Act, Industry, GLOBE, Immunoglobulin G, HPK1, R, Annual general meeting, Growth, SEC, Investment, Cancer, Clinical trial, Sale, NK, IND, Creativity, Large-cell lung carcinoma, Society, Security (finance), Annual report, American Society of Clinical Oncology, AML, Income, Patient, Myelodysplastic syndrome, Cell, COVID-19, Company, FLT3, Twitter, EGFR, D, Therapy, Partnership, TME, Tumor microenvironment, G&A, NASDAQ, Â, Research, Chemistry, Taiho Pharmaceutical, Nasdaq, CGEM, LinkedIn, Immune system, Investigational New Drug, Life insurance, Fine chemical, Pharmaceutical industry, Vaccine, Taiho

CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapeutic candidates across multiple modalities for patients with cancer, today reported on recent and upcoming business highlights and announced its financial results for the second quarter ended June 30, 2022.

Key Points: 
  • In collaboration with its partner, Taiho Oncology, Cullinan Oncology intends to initiate a pivotal study for CLN-081 in the second half of 2022 under the co-development agreement.
  • During the second quarter of 2022, we received cash proceeds of $270 million from the sale of Cullinan Pearl.
  • R&D Expenses: Research and development (R&D) expenses were $26.4 million for the second quarter of 2022, compared to $24.5 million for the first quarter of 2022.
  • G&A Expenses: General and administrative (G&A) expenses were $10.7 million for the second quarter of 2022, compared to $8.1 million for the first quarter of 2022.

Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl

Retrieved on: 
Thursday, May 12, 2022
Risk, Food, U.S. Securities and Exchange Commission, EDT, Nasdaq, Exercise, Patient, Investment, Health, Private Securities Litigation Reform Act, Lung cancer, CGEM, COVID-19, Taiho Pharmaceutical, FDA, Industry, Creativity, Urology, Partnership, Allergy, Drug discovery, Food and Drug Administration Amendments Act of 2007, Therapy, LinkedIn, Twitter, Immune system, Acquisition, SEC, Cancer, GLOBE, Security (finance), Investigational New Drug, Annual report, Medical imaging, Pharmaceutical industry, NSCLC, EGFR, Taiho

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Cullinan Oncology) (Nasdaq: CGEM) and Taiho Pharmaceutical Co., Ltd. (Taiho) today announced an agreement through which Taiho will acquire Cullinan Pearl Corp. (Cullinan Pearl) and co-develop and co-commercialize Cullinan Oncology’s lead program, CLN-081/TAS6417 (development code in Cullinan Oncology: CLN-081, development code in Taiho: TAS6417), an orally available, differentiated, irreversible EGFR inhibitor that selectively targets cells expressing EGFR exon 20 insertion mutations while sparing cells expressing wild-type EGFR. Subject to customary closing conditions, including expiration or termination of the waiting period under U.S. antitrust laws, the acquisition is expected to close in the second quarter of 2022.

Key Points: 
  • Cullinan Oncology will co-develop CLN-081/TAS6417 and will retain the option to co-commercialize CLN-081/TAS6417 in the United States together with Taiho Pharmaceutical through its U.S. subsidiary, Taiho Oncology, Inc. Taiho will commercialize CLN-081/TAS6417 in territories outside U.S. and China.
  • Utilizing Cullinan Oncologys unique business model through this strategic collaboration, we aim to hasten and maximize the development of CLN-081/TAS6417.
  • Together with Cullinan Oncology, the Taiho group will work to expeditiously deliver this agent to patients as soon as possible.
  • Taiho Pharmaceutical Co., Ltd., a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharma company with a focus on oncology.

Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris® I.V. Infusion 235mg in Japan

Retrieved on: 
Monday, March 28, 2022
Vomiting, Cisplatin, Heart, Sahachiro Hata, Antiemetic, Respect, Growth, Compliance, Urology, Environment, Cancer, Health, NCCN, Nausea, Donald Duck filmography, Quality of life, INT, Taiho Pharmaceutical, Society, Allergy, User experience, Corporation, Patient, Platinum, Dietary supplement, Pharmaceutical industry

235mg for adults, once on the first day of cancer chemotherapy,

Key Points: 
  • 235mg for adults, once on the first day of cancer chemotherapy,
    combined with other antiemetic drugs.
  • 2018; Ver.3
    3 Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al.
  • Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis.
  • Always putting customers first, Taiho Pharmaceutical also offers consumer healthcare products that support people's efforts to lead fulfilling and rewarding lives.

U.S. Food and Drug Administration (FDA) Accepts for Priority Review Taiho Oncology's New Drug Application for Futibatinib for Cholangiocarcinoma

Retrieved on: 
Wednesday, March 30, 2022
FGFR, CCA, Cholangiocarcinoma, State, DOR, FGFR2, HIV disease progression rates, Migraine, Caregiver, ORR, Common, Liver, Urology, AACR, American Association, BTD, Patient, Trae Crowder, Cancer, Health, Food, Neoplasm, Xerostomia, Senior, New Drug Application, Association, American Association for Cancer Research, Taiho Pharmaceutical, Hyperphosphatemia, ATP, Allergy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, Drug, Bile, PDUFA, Effectiveness, FGFR1, FDA, Toxicity, Hair, Pharmaceutical industry, Medical imaging, Taiho

Futibatinib is an investigational, oral, potent, selective and irreversible small-molecule inhibitor of FGFR1, 2, 3 and 4.

Key Points: 
  • Futibatinib is an investigational, oral, potent, selective and irreversible small-molecule inhibitor of FGFR1, 2, 3 and 4.
  • The FDA provided an anticipated Prescription Drug User Fee Act (PDUFA) action date of September 30, 2022.
  • It is this subset of patients with CCA that encompasses the NDA for futibatinib.
  • "The Taiho group, working as one, will continue to do its utmost to deliver this agent to those in need."

Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences’ Anti-TIGIT Program in Japan and Certain Territories in Asia

Retrieved on: 
Tuesday, November 30, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Patient, Private Securities Litigation Reform Act, Cancer, Durvalumab, Taiho Pharmaceutical, Achievement, Biology, NYSE, Exercise, Large-cell lung carcinoma, Partnership, Health, CD226, SEC, Urology, NK, AstraZeneca, Program, CD73, COVID-19, Physician, TIGIT, Twitter, List of life sciences, Allergy, PD-1, PHASE 2, CD155, Quality of life, Pharmaceutical industry, Vaccine, AB308, Zimberelimab, Taiho Pharmaceutical, Arcus Biosciences, AB308, ZIMBERELIMAB, TAIHO PHARMACEUTICAL, ARCUS BIOSCIENCES

This option exercise is based on an option and license agreement between Taiho and Arcus contracted in September 2017.

Key Points: 
  • This option exercise is based on an option and license agreement between Taiho and Arcus contracted in September 2017.
  • Taiho has already obtained exclusive rights to etrumadenant (AB928), an adenosine A2a/A2b receptor antagonist, and zimberelimab (AB122), an anti-PD-1 monoclonal antibody.
  • In Japan, Taiho is conducting a Phase 1 platform trial for zimberelimab in combination with other Taiho products.
  • Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.